Publicaciones archivos - Página 18 de 20

Human papillomavirus and anogenital pathology

Román R¹, Colomer A¹, Erill N¹, Calvo M³, Verdú M², Cordon-Cardo C⁴, Puig X^1,2.

¹BIOPAT, ²HISTOPAT Laboratoris and ³Statistics Dept. of the Universitat de Barcelona, Spain; and ⁴Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York.

Human papillomavirus (HPV) is the main etiologic factor for cervical cancer and its types are classified into low and high oncogenic risk according to their capability of inducing invasive tumors. We studied 978 paraffin-embedded anogenital biopsies (730 cervical plus 248 extracervical) for the presence of […]

Alberto 2003-07-23T17:55:01+00:00

Microsatellite analysis of chromosome 18 in colorectal cancer

Erill N¹, Colomer A¹, Calvo M³, Vidal A², Román R ¹, Verdú M², Cordon-Cardo C⁴, Puig X ^1,2.

¹BIOPAT, ²HISTOPAT Laboratoris, ³Statistics Dept. of the Universitat de Barcelona, Spain; and ⁴Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York.

Chromosome 18q allelic loss (c18q LOH) seems to have prognostic significance in stage II colorectal carcinoma. In our laboratory c18q LOH was prospectively analyzed in a series of primary colorectal tumors using five markers (D18S55/58/61/64 and 69). Results of 207 PCR-based assays […]

Alberto 2003-07-23T17:00:47+00:00

Lack of p53 nuclear immunostaining is not indicative of absence of TP53 gene mutations in colorectal adenocarcinomas

Anna Colomer,¹ Nadina Erill,¹ Montse Verdú,² Ruth Roman,¹ August Vidal,^1,2 Carlos Cordon-Cardo,^1,3 Xavier Puig^1,2

¹BIOPAT, Grup Assistència, Barcelona; ²HISTOPAT Laboratoris, Barcelona; and ³Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York.

Multiple studies using primary tumors have reported that alterations in p53 expression and detection of TP53 mutations are associated with clinical aggressiveness and poor response to specific therapies. However, there is no general agreement regarding the optimal technical approach to the analysis of p53. We have studied a series of […]

Alberto 2003-07-23T16:51:27+00:00

La mutación del P53 en los tumores vesicales. Su valoración mediante IHQ y PCR.

N. Hannaoui, N. Erill*, A. Colomer*, E. Vicente, A. Peña, E. Gómez, M. Verdú*, R. Román*, X. Puig*, JM. Banús

Institut Català d’Urologia i Nefrologia. * BIOPAT. Biopatologia molecular, S.L. Grup Assistència.

Texto completo

Póster presentado en:

LXVIII CONGRESO DE UROLOGÍA

Las Palmas de Gran Canaria, España, 24-28 Mayo 2003

Abstract: Actas Urológicas Españolas 2003;27(4SUPPL 1):182.

Alberto 2003-05-24T14:25:40+00:00

HER-2/neu status in breast carcinoma: overexpression versus amplification

Verdú M^1,Colomer A^2,Román R^2,Erill N^2,Moreno A^1,Cordón-Cardo C^1,2,Puig X^1,2.

¹HISTOPAT Laboratoris & ²BIOPAT. Grup Assistència. Barcelona (Spain).

HER-2/neu is a critical marker in assessing the molecular profile of breast cancer, as it represents a target for therapeutic intervention. HER-2/neu gene amplification has been reported to be associated with treatment response. Immunohistochemistry (IHC) to detect HER-2/neu protein overexpression was initially recommended as the technique of choice to assign patients to Herceptin clinical treatment. However, different studies have shown […]

Alberto 2003-02-23T17:27:24+00:00

Previous 16 17 18 19 20 Next